2 completed, 1 terminated. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow propagermanium: new trials by email Literature Review of propagermanium trials Research Report on propagermanium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the Treatment of COVID-19 Candesartan Cilexetil, Repagermanium, Candesartan Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 | Terminated | University of Sydney | 49 | 2022-01-07 | 2023-09-15 |
| Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan Propagermanium, Placebo - Focal Segmental Glomerulosclerosis | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 8 | 2018-11-08 | 2022-07-29 |
| Safety and Effectiveness of Propagermanium in Diabetic Kidney Disease Participants Receiving Irbesartan Propagermanium, Placebo - Diabetic Kidney Disease | Phase 2 | Completed | Dimerix Bioscience Pty Ltd | 45 | 2018-11-06 | 2022-07-29 |
COVID-19 (1) · Diabetic Nephropathies (1) · Glomerulosclerosis, Focal Segmental (1)
Dimerix Bioscience Pty Ltd (2) · University of Sydney (1)
Australia (2) · India (1)
Simon Roger, MD (2) · Meg Jardine (1) · Vivekanand Jha (1)